 PLYMOUTH MEETING, Pa., June 7, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that results from two post-hoc analyses from the clinical development program for WAKIX pitolisant will be presented at the 35th Annual Meeting of the Associated Professional Sleep Societies APSS, known as SLEEP 2021. 